Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) shares rose 13.5% on Monday. The company traded as high as $0.3169 and last traded at $0.3169. Approximately 5,900 shares traded hands during trading, a decline of 29% from the average session volume of 8,313 shares. The stock had previously closed at $0.2791.
Defence Therapeutics Price Performance
The business’s fifty day simple moving average is $0.33 and its 200 day simple moving average is $0.35.
About Defence Therapeutics
Defence Therapeutics Inc is a Canadian biotechnology company focused on developing drug-delivery technologies and therapeutic candidates for cancer and other serious diseases. Its work centers on the Accum platform, which is designed to improve the delivery of biologic medicines into cells and enhance the effectiveness of treatments such as vaccines, antibody-drug conjugates and immunotherapies.
The company’s development programs include AccuTOX, an oncology candidate intended to support targeted cancer treatment and immune activation, as well as AccuVAC vaccine applications designed to improve the delivery and performance of antigen-based vaccines.
Recommended Stories
- Five stocks we like better than Defence Therapeutics
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
